A report by the American “CNN” network considered that the presence of two doses will cause a real problem, as some logistical problems, indicating the difficulty of purchasing test kits and preventive equipment, and even the problem of distributing double doses in each country. Other concerns center on the human nature, which is the difficulty in persuading people to get the vaccine twice and not once, and this is not easy.
“There is no doubt that this will be the most complex and largest vaccination program in human history, and this will require a level of effort and a level of development, which we have not tried before,” said Dr. Kelly Moore, a professor of health policy at Vanderbilt University in the US.
So far, RapSpeed, the program that indicates the US government’s efforts to get a vaccine on the market, has provided funds to six pharmaceutical companies in order to lay off the creation of a vaccine against Corona. Two of these companies, “Moderna” and “Pfizer”, are underway. Now is the third phase of large-scale clinical trials. The 30,000 volunteers in each trial receive two doses, with a spacing of 28 days between each dose in Moderna and in Pfizer, 21 days apart.
British pharmaceutical company AstraZeneca is expected to start phase III trials this month. The Phase I and Phase II trials used two doses 28 days apart.
The American company “Novafex” also did not start the third phase trials, but it used two doses in its previous experiments. As for the American company, Johnson & Johnson, some participants will take one dose and others will take two doses.
The French company “Sanofi” did not announce whether its vaccine was in one or two doses.
It is not surprising that the expected Corona vaccine will likely need two doses, as many vaccines – including childhood vaccines against chickenpox and hepatitis C – require two doses.
According to the American Network, some need more than that, for example, children receive five doses of the vaccine that protects them from diphtheria, tetanus and whooping cough.
And it’s not just producing the vaccines themselves, but also supplying, “We are looking at double doses,” said Nada Sanders, a professor of supply chain management at Northeastern University. That’s double the amount. Doubling is a huge issue in the supply chain. ”
“You have to multiply everything in the supply chain,” Sanders said. Syringes, can they double? Can flasks double? Can tampons double? Can the needles double? Everything has to be doubled, and then they all have to get it in time in the various entities along the supply chain. ”
And Sanders considered that the probability of failure to supply possible doses of the vaccine is high.
On the other hand, it seems that it will be difficult to get the majority of Americans to come once to get vaccinated, it will not be easy when they have to be persuaded to attend twice.
And according to a CNN poll conducted this month, 40 percent of Americans said they would not receive the vaccine, even if it was free and easy to obtain.
“These are the things that I think we need to think about, to make sure that we can motivate people to make it as easy as possible,” said Dr. Nelson Michael, director of the Infectious Diseases Research Center at Walter Reed Military Research Institute, who is tasked with working with Operation Rap Speed. It is possible for them to adhere to the dual injection system. ”
Michael, who has worked on vaccination campaigns before, said the challenges are real. “I think if you give the public health community this jurisdiction, they’ll find a way,” he said. But the task will be very difficult ».
It is worth noting that the United States is approaching this morning (Monday) the threshold of six million infection with the emerging coronavirus, the epidemic that has infected more than 25 million people in the world, as measures to ease isolation measures coincide with the imposition of restrictions to contain the outbreak of the disease.
About 5,993,668 people have been infected with the virus, of whom 183,034 people have died in the United States as of 00:30 GMT Monday, according to a Johns Hopkins University reference tally. This country is considered the most affected by the epidemic, which has killed more than 843,000 people in the world.